Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans

Abstract EN

Effective immunotherapy for cancer depends on cellular responses to tumor antigens.

The role of major histocompatibility complex (MHC) in T-cell recognition and T-cell receptor repertoire selection has become a central tenet in immunology.

Structurally, this does not contradict earlier findings that T-cells can differentiate between small hapten structures like simple glycans.

Understanding T-cell recognition of antigens as defined genetically by MHC and combinatorially by T cell receptors led to the “altered self” hypothesis.

This notion reflects a more fundamental principle underlying immune surveillance and integrating evolutionarily and mechanistically diverse elements of the immune system.

Danger associated molecular patterns, including those generated by glycan remodeling, represent an instance of altered self.

A prominent example is the modification of the tumor-associated antigen MUC1.

Similar examples emphasize glycan reactivity patterns of antigen receptors as a phenomenon bridging innate and adaptive but also humoral and cellular immunity and providing templates for immunotherapies.